BioSpace News Archive

Castle Creek Biosciences, Inc, a privately-held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized therapies for underserved disorders with high unmet medical needs, today announced the first patient has been dosed in the DeFi-RDEB Phase 3 clinical trial evaluating debcoemagene autoficel (D-Fi

E25Bio, innovators of rapid diagnostics and digital health platforms, announced today that Prashant Chouta has been named chief executive officer. “We are thrilled to welcome Prashant to E25Bio. Prashant comes to the team with a history of success at some of the largest companies in the world. His leadership will undoubtedly help guide E25Bio into its next phase and beyond as it looks to revolutionize pandemic respon

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high-quality cannabis, announced today that Victor Mancebo has resigned from the Board of Directors and his role as Chief Executive Officer, effective December 31, 2020.

NeuroEM Therapeutics is poised to deliver a knockout blow to Alzheimer’s disease. The clinical-stage medical device company is pleased to announce FDA Breakthrough Device designation for its bioengineered head device shown to reverse Alzheimer’s memory loss in its pilot study, published last fall in the Journal of Alzheimer’s Disease.

The Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics announced a partnership to support the advancement of the company’s universal G-NK cell therapy into clinical trials for the treatment of patients with multiple myeloma

Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available. This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that it has begun field testing to evaluate the emergence and agronomics of winter Camelina sativa varieties.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today the Company has begun recruiting and enrolling patients in a Phase I multi-center, randomized, controlled trial for a total of 40 patients that will assess the safety and efficacy of inhaled Ampion

Kantaro Biosciences, LLC (“Kantaro”), a joint venture between the Mount Sinai Health System and RenalytixAI plc (LSE: RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), entered into a two-year marketing and distribution agreement with EKF Diagnostics, a global leader in diagnostic testing.

Data presented by Invitae (NYSE: NVTA), a leading medical genetics company, at the American Society of Human Genetics (ASHG) Virtual Meeting found one in ten men with prostate cancer harbor genetic changes linked to hereditary cancer syndromes and three-quarters of those patients met criteria for changes in cancer management or treatment based on their genetic findings.